Clinical Trial Update: High Dose IMVAMUNE® in Vaccinia-Naive Individuals [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a high-dose IMVAMUNE smallpox vaccine in vaccinia-naive adults; results were posted in 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Smallpox

Drugs mentioned

• IMVAMUNE (Modified Vaccinia Ankara (MVA))

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Smallpox | Phase 2 | Status: COMPLETED | Results posted: 2025-06-13